A great deal of medical technology being utilized in the Florida Heart and Lung Institute involves procedures that are done through the skin. The word that you often hear for this trend is percutaneous. Among the newest of these procedures, Transcatheter Mitral Valve Replacement, has begun being performed at the North Florida Regional Medical Center, and only one other facility in the state. Similar to Aortic Valve Replacement surgery, this transcatheter valve therapy (TVT) provides unprecedented to patients with valvular heart disease (VHD). This month, we are quite proud to begin enrolling patients for this transformational procedure. The implant is made up of multiple parts: atrial brim, outer fixation ring, inner stent, and inner valve leaflets.
These percutaneous procedures have been in existence for around a decade, however their current and future advancement is what keeps medical practitioners, including the ones in Gainesville, and viable candidates on the tips of their toes. As the research and development continues with procedures such as TMVR, patients that were previously deemed too high-risk are now becoming viable matches for the new operations. As the enrollment for TMVR begins this month, we’re going to begin exhibiting the initial results of NFRMC’s trial and adoption of yet another 21st century creation. While there are several determining factors when it comes to a patient’s eligibility, such as the presence of prohibitive mitral annular calcification, an overarching element of this caliber of operation could be stated as its inclusivity amongst viable patients.
As our cardiovascular program grows, we will continue to adopt new technologies in the field of cardiovascular surgery. Valvular heart diseases, or VHD, are inherently prone to risks, which is why these procedures are exactly as groundbreaking as they are claimed to be. Our December 2018 launch of TMVR is just a stepping stone in the future of our heart healthy patients.
In the near future, Florida Heart and Lung will begin stacking up the statistics behind this new mitral trial and more specifically what it means for our community and beyond.